JATT II Acquisition Corp. Finalizes Business Combination with Talawar Therapeutics, Securing $225M PIPE
JATT sits 18% above its 52-week low of $10 on light trading volume (0.1× avg).
Summary
JATT II Acquisition Corp. announced a definitive business combination agreement with Talawar Therapeutics, a biotech company, securing $225 million in PIPE financing to fund its lead drug candidate through Phase 2b trials.
Key Events · M&A and Partnerships · JATT
-
Definitive Business Combination
JATT II Acquisition Corp. entered a definitive agreement to merge with Talawar Tx Inc., a biotechnology company, with the combined entity to be named Talawar Therapeutics and listed on Nasdaq under "TLWR".
-
Substantial PIPE Financing
A $225 million private placement of 22.5 million shares at $10.00 per share was secured, providing significant capital for the combined company.
-
Funding for Clinical Development
The capital raised is anticipated to fund Talawar's lead bispecific antibody candidate, TALA-125, through a Phase 2b proof-of-concept study data readout in the second half of 2028.
-
Sponsor Support & Share Surrender
JATT's sponsor agreed to vote in favor, waive anti-dilution rights, and surrender 150,000 JATT Ordinary Shares, reducing potential dilution for public shareholders.
Analysis · JATT · Real Estate & Construction
JATT II Acquisition Corp. has entered into a definitive agreement to merge with Talawar Tx Inc., a biotechnology company. This transaction will bring Talawar Therapeutics public with substantial funding. The $225 million PIPE financing, priced at $10.00 per share (below the current market price of $11.75), combined with JATT II's trust account, is expected to provide $285 million in available cash (assuming no redemptions). This capital is crucial for funding Talawar's lead bispecific antibody candidate, TALA-125, through a Phase 2b proof-of-concept study data readout in the second half of 2028. The deal includes a minimum cash condition of $125 million for closing, ensuring adequate funding for the combined entity.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JATT was trading at $11.75 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $83.5M. The 52-week trading range was $10.00 to $12.01. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.